AnaptysBio (NASDAQ:ANAB) Now Covered by Analysts at SVB Leerink

Analysts at SVB Leerink assumed coverage on shares of AnaptysBio (NASDAQ:ANAB) in a research report issued on Tuesday, Marketbeat Ratings reports. The brokerage set an “outperform” rating and a $47.00 price target on the biotechnology company’s stock. SVB Leerink’s target price indicates a potential upside of 118.91% from the company’s previous close.

A number of other research analysts have also recently issued reports on the stock. Stifel Nicolaus began coverage on shares of AnaptysBio in a report on Wednesday, February 21st. They set a “buy” rating and a $50.00 price objective for the company. JPMorgan Chase & Co. cut their price target on shares of AnaptysBio from $30.00 to $28.00 and set a “neutral” rating on the stock in a research note on Monday, April 1st. BTIG Research began coverage on shares of AnaptysBio in a research note on Monday, February 26th. They issued a “buy” rating and a $55.00 price target on the stock. Wells Fargo & Company began coverage on shares of AnaptysBio in a research note on Thursday, April 11th. They issued an “overweight” rating and a $56.00 price target on the stock. Finally, Wedbush raised shares of AnaptysBio from a “neutral” rating to an “outperform” rating and lifted their price target for the company from $20.00 to $34.00 in a research note on Tuesday, March 12th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and seven have given a buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $46.22.

AnaptysBio Price Performance

Shares of NASDAQ:ANAB opened at $21.47 on Tuesday. AnaptysBio has a one year low of $13.36 and a one year high of $27.50. The company has a 50 day moving average of $23.38 and a 200-day moving average of $20.55. The stock has a market cap of $574.54 million, a price-to-earnings ratio of -3.53 and a beta of -0.30.

AnaptysBio (NASDAQ:ANAB) last issued its quarterly earnings data on Monday, March 11th. The biotechnology company reported ($1.59) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.74) by $0.15. The firm had revenue of $9.01 million during the quarter, compared to analysts’ expectations of $3.28 million. AnaptysBio had a negative net margin of 953.66% and a negative return on equity of 119.42%. Equities research analysts anticipate that AnaptysBio will post -6.25 earnings per share for the current year.

Insider Transactions at AnaptysBio

In other news, CEO Daniel Faga sold 3,000 shares of the business’s stock in a transaction on Monday, March 25th. The shares were sold at an average price of $21.42, for a total value of $64,260.00. Following the sale, the chief executive officer now owns 749,087 shares of the company’s stock, valued at $16,045,443.54. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. In other AnaptysBio news, CEO Daniel Faga sold 3,000 shares of the company’s stock in a transaction on Monday, March 25th. The shares were sold at an average price of $21.42, for a total transaction of $64,260.00. Following the sale, the chief executive officer now directly owns 749,087 shares of the company’s stock, valued at $16,045,443.54. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Eric J. Loumeau sold 5,000 shares of the company’s stock in a transaction on Friday, February 16th. The stock was sold at an average price of $25.00, for a total transaction of $125,000.00. Following the sale, the insider now directly owns 3,240 shares in the company, valued at $81,000. The disclosure for this sale can be found here. Insiders have sold a total of 157,005 shares of company stock valued at $3,586,199 over the last 90 days. 35.50% of the stock is owned by corporate insiders.

Institutional Trading of AnaptysBio

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Quantbot Technologies LP bought a new stake in AnaptysBio during the second quarter worth $34,000. China Universal Asset Management Co. Ltd. increased its holdings in shares of AnaptysBio by 350.4% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 3,072 shares of the biotechnology company’s stock valued at $66,000 after purchasing an additional 2,390 shares during the last quarter. Tower Research Capital LLC TRC increased its holdings in shares of AnaptysBio by 248.8% in the third quarter. Tower Research Capital LLC TRC now owns 3,596 shares of the biotechnology company’s stock valued at $65,000 after purchasing an additional 2,565 shares during the last quarter. BNP Paribas Arbitrage SA increased its holdings in shares of AnaptysBio by 75.4% in the second quarter. BNP Paribas Arbitrage SA now owns 4,984 shares of the biotechnology company’s stock valued at $101,000 after purchasing an additional 2,142 shares during the last quarter. Finally, Quest Partners LLC acquired a new position in shares of AnaptysBio in the fourth quarter valued at $119,000.

About AnaptysBio

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.